Search Results - "Fidalgo, J.A. Perez"

Management of chemotherapy extravasation: ESMO–EONS clinical practice guidelines by Pérez Fidalgo, J.A., MD, García Fabregat, L., RN, Cervantes, A., MD, Margulies, A., RN, Vidall, C., RN, Roila, F., MD

“…Discusses risk factors, prevention, diagnosis, documentation, and follow up for extravasation. The article explains management issues, highlighting the use of…”
Get full text

Current questions for the treatment of advanced gastric cancer by Cervantes, A, Roda, D, Tarazona, N, Roselló, S, Pérez-Fidalgo, J.A

“…Abstract Background Gastric cancer remains a major health problem worldwide. Treatment of advanced gastric cancer is controversial and there is no standard…”
Get full text

138 Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer by Ibarrola-Villava, M, Llorca-Cardeñosa, M.J, Tarazona, N, Mongort, C, Fleitas, T, Perez-Fidalgo, J.A, Rosello, S, Navarro, S, Ribas, G, Cervantes, A

Get full text

160 AKT and/or mTOR inhibition as a potential target in trastuzumab resistant breast cancer cells with MUC-4 overexpression by Perez-Fidalgo, J.A, Espin, E, Tormo, E, Pineda, B, Cejalvo, J.M, Sabbaghi, M.A, Alonso, E, Rovira, A, Rojo, F, Albanell, J, Bermejo, B, Burgues, O, Lluch, A

Get full text

Integrating radical local treatment of the primary in the management of stage IV breast cancer. When is the best moment for the resection of the primary tumor? by Perez-Fidalgo, J.A, Caballero, A, Lluch, A

Get full text

Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines by Pérez Fidalgo, J A, García Fabregat, L, Cervantes, A, Margulies, A, Vidall, C, Roila, F

Get full text

158P In silico analysis of HER2 enriched subtype and a HER2 index based on transcriptomic data of breast cancer compared to gastric and uterine serous carcinomas by Gonzalez-Vilanova, A., Fleitas, T.C., Gaba Garcia, L., Zuniga-Trejos, S., Perez Fidalgo, J.A.

Get full text

585P Trabectedin induces apoptosis regardless of acquired resistance to PARP inhibitors in BRCA2 mutant high grade ovarian cancer cell lines by Perez Fidalgo, J.A., Sanchez-Serrano, P., Heredia, V., Martinez Pretel, J.J., Hochstadt, J., Mendiola, M., Redondo Sanchez, A., Burgués, O., Pineda Merlo, B.

Get full text

1820P Taxane-related skin toxicity: Analysis of an in vivo and 3D in vitro model study of the impact of paclitaxel on skin by Perez-Leal, M., Perez Fidalgo, J.A., Sanz, C., Poveda, J., Milara, J., Martinez, P., Cervantes, A., Cortijo, J.

Get full text

18P In vitro analysis of the combination of APR-246 and carboplatin in triple negative breast cancer (TNBC) and high grade serous ovarian cancer (HGSOC) cell lines and its impact on Aurora kinase A (AURKA)-p53 pathway by Martinez-Pretel, J.J., Pineda, B., Eguez, K., Ortega Morillo, B., Hochstadt, J., Monzon, M., Lluch-Hernandez, A., Cervantes, A., Perez Fidalgo, J.A.

Get full text

734P Neutrophil-lymphocyte ratio predicts survival in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD): Stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601 by Fidalgo, J.A. Perez, Cortés, A., García, Y., Iglesias, M., Sarmiento, U. Bohn, García, E. Calvo, Manso, L., Santaballa, A., Oaknin, A., Redondo, A., Rubio, M.J., González-Martín, A.

Get full text

583P Aurora kinase overexpression may play a role in PARPi resistance in tumor samples of patients with high grade ovarian cancer and its inhibition with alisertib overcomes resistance to olaparib in a PARPi-resistant cell line model by Perez Fidalgo, J.A., Martinez Pretel, J.J., Heredia, V., Romeo Marin, M., Mendiola, M., Hochstadt, J., Bernat, A., Sanchez-Serrano, P., Redondo Sanchez, A., Gil Martín, M., Guerra Ojeda, S., Teruel, I., Burgués, O., Cervantes, A., Pineda Merlo, B.

Get full text

LBA37 Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial by Gonzalez Martin, A., Rubio Perez, M.J., Heitz, F., Christensen, R.D., Colombo, N., Van Gorp, T., Oaknin, A., Leary, A., Gaba Garcia, L., Lebreton, C., De Sande González, L.M., Romeo Marin, M., Redondo, A., Barretina Ginesta, M.P., Perez Fidalgo, J.A., Santaballa Bertran, A., Bermejo-Pérez, M.J., Bruchim, I., Ray-Coquard, I.L., Selle, F.

Get full text

Lenvatinib plus pembrolizumab a new effective combination of targeted agents by Perez-Fidalgo, J.A., Martinelli, E.

Get full text

2068 POSTER Incidence of amenorrhea after chemotherapy and paper of hormone therapy in the ovarian function in hormone sensitive breast cancer by Garcia Garre, E, Roselló, S.R, Jorda, E, Perez-Fidalgo, J.A, Martin, P, Bermejo, B, Magro, A, Chirivella, I, Lluch, A

Get full text

832P GEICO1601-ROLANDO trial: A multicentric single arm phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer by Perez Fidalgo, J.A., Cortés, A., García, Y., Iglesias, M., Bohn Sarmiento, U., Calvo García, E., Manso Sánchez, L., Santaballa, A., Oaknin, A., Redondo, A., Rubio, M.J., González Martín, A.

Get full text

28P Collagen-activated signalling pathway is significantly hypermethylated in high-grade serous ovarian cancer (HGSOC) patients treated with platinum-containing neoadjuvant chemotherapy (NACT) by Fidalgo, J.A. Perez, Burgues, O., Morillo, B. Ortega, Pretel, J.J. Martinez, Ruiz-Linuesa, M., Barrallo, I. Gonzalez, Sanchez-Serrano, P., Segui-Manzaneque, V., Merlo, B. Pineda

Get full text

134P Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance by Fidalgo, J.A. Perez, Pretel, J.J. Martinez, Sanchez-Serrano, P., Heredia, V., Mendiola, M., Sanchez, A. Redondo, Burgues, O., Merlo, B. Pineda

Get full text

Intraperitoneal chemotherapy (IP CT) after cytoreductive surgery benefits survival in epithelial ovarian cancer (EOC): Results of a pooled meta-analysis including 9 randomized clinical trials (RCT) by Jimenez-Heredia, M., Perez Fidalgo, J.A., Morales Suarez-Varela, M., Sanchis, J., Aranda, M., Cervantes, A.

Get full text

The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach by Adam-Artigues, A., Tormo, E., Rojo, F., Perez-Fidalgo, J.A., Zazo, S., Gonzalez-Alonso, P., Hernando, C., Martínez, M.T., Gambardella, V., Poveda, J., Simón, S., Moragon, S., Alonso, E., Albanell, J., Burgues, O., Bermejo, B., Eroles, P., Lluch, A., Cejalvo, J.M., Rovira, A.

Get full text